Origami Therapeutics announced a global collaboration with Ipsen to advance a protein‑degrader drug discovery program focused on targeted protein degradation. The agreement covers discovery and development of degrader candidates with Origami retaining discovery roles and Ipsen providing development and commercialization expertise. The deal combines Origami’s degrader platform capabilities with Ipsen’s oncology R&D infrastructure and global reach. Financial terms were not disclosed in the announcement, but the collaboration aims to accelerate degrader programs into clinical development. For companies pursuing novel modalities, the partnership signals continued pharma interest in PROTACs and degrader strategies as complementary approaches to conventional inhibition, and highlights deal‑making as a route to de‑risking early degrader pipelines.